Bleeding in people with multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at bleeding in people who have just been diagnosed with multiple myeloma. If you join, you will answer questionnaires so the researchers can understand who is more likely to bleed while taking blood-thinning medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of multiple myeloma (a blood cancer affecting plasma cells).
- You need to be taking a blood-thinner medicine like aspirin or low-molecular-weight heparin (e.g., enoxaparin) to prevent blood clots.
- You must be willing and able to answer questionnaires as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.